GLP-1 agonists like semaglutide drive meaningful weight loss, but a growing body of evidence points to a critical trade-off: significant lean mass reduction, particularly in older patients. New data presented by Veru at ObesityWeek 2026 quantifies that trade-off in adults 65 and older — and shows a selective androgen receptor modulator (SARM) may help close the gap.

In a post hoc analysis of patients aged 65 and older drawn from Veru's Phase 2b QUALITY study, participants receiving semaglutide plus placebo lost significant lean mass over 16 weeks and demonstrated measurable declines in physical function, including reduced stair-climb power and slower stair-climb time — despite achieving clinically meaningful weight reduction. The functional endpoints matter: stair-climb power is an established proxy for lower-extremity strength and fall risk in older populations.

The Enobosarm Effect

Participants in the same age cohort who received semaglutide combined with enobosarm — Veru's investigational oral SARM — preserved both lean mass and stair-climb physical function at the 16-week clinical endpoint. Enobosarm works by selectively activating androgen receptors in muscle and bone tissue, targeting anabolic pathways without the broader hormonal effects associated with traditional androgens. The compound has been evaluated across multiple studies in cancer-related muscle wasting, giving it a relatively well-characterized safety and mechanism profile.

The findings land squarely in a conversation the nutraceutical and functional nutrition sectors are increasingly part of. As GLP-1 adoption accelerates — with millions of patients now on semaglutide or tirzepatide — dietitians, sports nutritionists, and supplement formulators have flagged muscle preservation as a significant co-intervention opportunity. Protein fortification, leucine-enriched formulas, creatine, and HMB (beta-hydroxy beta-methylbutyrate) are already being positioned by finished-formulation brands as GLP-1 companion nutrition products targeting this exact clinical gap.

Market Context

The GLP-1 adjacency segment is one of the fastest-emerging opportunity spaces in functional nutrition. Ingredient suppliers and contract manufacturers are actively developing white-label and co-manufacturing programs around muscle-sparing stacks — protein concentrates, essential amino acid blends, and creatine monohydrate — specifically marketed to patients on weight-loss medications. While enobosarm is a pharmaceutical-track compound rather than a dietary ingredient, its clinical data directly validates the physiological concern that nutraceutical brands are building product strategy around: GLP-1-induced sarcopenia risk, especially in adults over 60.

For operators tracking the intersection of weight management and healthy aging, the QUALITY study data reinforces what category observers have argued for over a year — that GLP-1 weight loss without lean mass protection represents an incomplete clinical outcome. Brands developing protein and muscle-health formulations or healthy-aging supplement lines now have peer-reviewed clinical endpoints to anchor structure-function claims and consumer education around the muscle-loss risk accompanying rapid GLP-weight reduction.

Veru has not announced a regulatory filing timeline for enobosarm in the obesity-plus-GLP-1 indication, but ObesityWeek presentations typically precede or accompany peer-reviewed publication, and the data are expected to inform ongoing Phase 3 program design.

Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.